Mankind Pharma earnings date: Key numbers for May 2026

Upcoming earnings date and what is scheduled

Mankind Pharma Ltd.’s upcoming earnings date is listed as 19 May 2026 for Q4 FY26-27. The last earnings date captured in the provided data is 3 February 2026 for Q3 FY25-26. For investors tracking near-term triggers, the 19 May date matters because it is the next official checkpoint for updates on growth, margins, and integration benefits from recent consolidation.

Q3 snapshot: revenue, gross profit and net profit trends

For the latest quarter referenced in the dataset, Mankind Pharma reported revenue of ₹2,632 crore, up 0.92% quarter-on-quarter (QoQ) and 9.85% year-on-year (YoY). Gross profit was reported at ₹670 crore, up 12.86% QoQ and 2.55% YoY. Net profit came in at ₹449 crore, down 2.05% QoQ but up 7.95% YoY.

These figures indicate that while profitability grew compared with the same period last year, the sequential profit movement was softer even as gross profit improved QoQ. Investors typically read this mix as a signal to watch operating costs and other below-the-line movements in the upcoming quarter.

Standalone December 2025 results: sales, profit, EBITDA and EPS

The company’s standalone quarterly numbers for December 2025 showed net sales of ₹2,632.68 crore, up 9.85% YoY from ₹2,396.57 crore in December 2024. Quarterly net profit stood at ₹449.47 crore, up 7.95% YoY from ₹416.38 crore. EBITDA was reported at ₹834.77 crore, up 2.96% YoY from ₹810.75 crore.

On per-share profitability, EPS increased to ₹10.89 in December 2025 from ₹10.35 in December 2024. In addition to earnings metrics, the data also notes that the last dividend was ₹1.00 per share, paid on 08 August 2025.

Stock price reference around the last earnings date

As per the provided information, Mankind Pharma shares closed at ₹2,089.30 on 03 February 2026 (NSE). This close is a useful reference point for readers comparing how the stock behaves around results and how expectations are priced in ahead of the next update.

FY25 Q4: revenue surge, but profit and margin pressure

For the quarter ended March 2025 (Q4 FY25), multiple reports in the supplied text describe a strong topline with softer profitability. Revenue from operations was reported at ₹3,079 crore, up 27% YoY (also cited as ₹3,079.40 crore, up 27.10%).

On profits, one report cited a 10.70% YoY decline in consolidated net profit to ₹420.80 crore (from ₹471.20 crore), while another cited consolidated net profit at ₹424.65 crore (from ₹476.59 crore). EBITDA for the quarter was reported at ₹683.20 crore (up 16.50%) and also cited at ₹686 crore, with EBITDA margin reported at 22.20% or 22.3%, compared with 24.20% or 24.3% in the prior-year quarter.

Domestic and exports: Q4 FY25 business mix from reported data

The same Q4 FY25 coverage highlighted the role of domestic demand and exports. Domestic revenue rose 18% to ₹2,544 crore (from ₹2,155 crore), while exports increased 100% YoY to ₹535 crore in the March quarter. The company also reported that its share in the domestic market increased from 4.4% in March 2024 to 4.8% as of March 2025, with the improvement linked to the BSV acquisition and strength in gynaecology.

BSV consolidation and margin targets cited in the narrative

The text notes that the deal for Bharat Serums and Vaccines (BSV) closed in October 2024, making Q4 FY25 the first full quarter with BSV fully consolidated. BSV margins were described as being around 26% to 27%, with a plan to improve margins by 50 to 100 basis points a year and a longer-term goal of reaching 30% by FY30, subject to R&D investments.

Full-year FY25: revenue, domestic milestone and exports growth

For the full year FY25, Mankind Pharma’s revenue was reported at ₹12,207 crore, reflecting 19% YoY growth. Adjusted EBITDA was reported at ₹3,159 crore with a margin of 25.9%. On segment splits, domestic revenue crossed ₹10,675 crore (up 13% YoY) and exports rose 88% to ₹1,532 crore.

How the market reacted during prior result days

Price action in the text shows that results have sometimes been followed by volatility. After Q4 FY25 results (dated 22 May 2025 in the provided excerpt), the stock was reported down about 3.57% at ₹2,441 versus a previous close of ₹2,531.40 on NSE, with an intraday high of ₹2,484.80 and low of ₹2,430. Another reference in the supplied content notes a close of ₹2,533.03 on BSE, down 0.69%, and elsewhere a close of ₹2,530, down 0.75%.

Key reported numbers at a glance

Why the May 2026 earnings update matters

With the next earnings date approaching, the reported history points to three measurable themes investors typically track: (1) whether revenue growth sustains after periods of strong YoY expansion, (2) how margins behave when consolidation and mix changes are in play, and (3) whether exports and domestic chronic segments continue to contribute meaningfully.

The provided data also shows that topline momentum has coexisted with quarters of softer profit growth or margin contraction. That makes the upcoming earnings date an important checkpoint for confirming whether profitability is stabilising alongside growth.

Conclusion

Mankind Pharma’s next earnings are scheduled for 19 May 2026, following a recent trail of reported sales growth and mixed profit and margin outcomes across quarters. Investors will be watching for updated financials, margin commentary, and any further details around BSV’s contribution when the company reports on the scheduled date.